Fortunately there are still plenty of great people in the medical community who are trying to find a solution to problems other than their bank accounts. Not only is this important in terms of saving lives and quality of life, but it's also damned important to countries who need to improve the quality of care but do so in a more cost effective way.
The days of one-size-fits-all cancer treatment are numbered: A rush of new research is pointing the way to tailor chemotherapy and other care to what's written in your tumor's genes.Read More......
Everyone with advanced colon cancer now is supposed to get a genetic test before taking two of the leading treatments. It's a major change adopted by oncologists last month after studies found that those pricey drugs, Erbitux and Vectibix, won't work in 40 percent of patients.
Scientists are furiously testing similar genetically tailored care in breast and lung cancer. It's a flurry of work that reflects a huge problem: Most medications today benefit at best about half of patients but it usually takes trial-and-error to tell.
That means a lot of people suffer side effects for nothing, and it's incredibly costly. When the American Society of Clinical Oncology recommended giving colon cancer patients that $300 test for a gene called KRAS, it estimated the move could save a stunning $600 million a year — by keeping drugs that cost up to $10,000 a month away from patients who won't benefit.